Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Panchapakesan, Usha ^a   Pegg, Kate ^a   Gross, Simon ^a   Komala, Muralikrishna Gangadharan ^a   Mudaliar, Harshini ^a   Forbes, Josephine ^b   Pollock, Carol ^a   Mather, Amanda ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE TRANSPORTER 2; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; SMAD3 PROTEIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; TOLL LIKE RECEPTOR 4;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION;

BENZHYDRYL COMPOUNDS; COLLAGEN TYPE IV; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; EPITHELIAL CELLS; GENE EXPRESSION; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-6; KIDNEY TUBULES, PROXIMAL; NF-KAPPA B; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SMAD3 PROTEIN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84873497173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054442     Document Type: Article

References (30)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, et al. (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539.
2. Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA (2011) SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus. J Clin Pharmacol.
3. Vallon V, Sharma K, (2010) Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens 19: 425-431.
4. Johnson DW, Saunders HJ, Brew BK, Poronnik P, Cook DI, et al. (1998) TGF-beta 1 dissociates human proximal tubule cell growth and Na(+)-H+ exchange activity. Kidney Int 53: 1601-1607.
5. Panchapakesan U, Pollock CA, Chen XM, (2004) The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol 287: F528-534.
6. Qi W, Chen X, Holian J, Mreich E, Twigg S, et al. (2006) Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells. Am J Physiol Renal Physiol 291: F1070-1077.
7. Nicolle LE, Capuano G, Ways K, Usiskin K, (2012) Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 28: 1167-1171.
8. Gilbert RE, Cooper ME, (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56: 1627-1637.
9. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, et al. (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556-563.
10. Panchapakesan U, Sumual S, Pollock CA, Chen X, (2005) PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 289: F1153-1158.
11. Pollock CA, Field MJ, Bostrom TE, Dyne M, Gyory AZ, et al. (1991) Proximal tubular cell sodium concentration in early diabetic nephropathy assessed by electron microprobe analysis. Pflugers Arch 418: 14-17.
12. Pollock CA, Lawrence JR, Field MJ, (1991) Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol 260: F946-952.
13. Holian J, Qi W, Kelly DJ, Zhang Y, Mreich E, et al. (2008) Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 295: F1388-1396.
14. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, et al. (2005) Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis. Am J Physiol Renal Physiol 288: F800-809.
15. Mather A, Pollock C (2011) Glucose handling by the kidney. Kidney Int Suppl: S1-6.
16. Wright EM, (2001) Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280: F10-18.
17. Mather A, Pollock C, (2010) Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol 6: 307-311.
18. Aires I, Calado J, (2010) BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs 11: 1182-1190.
19. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF, (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.
20. Musso G, Gambino R, Cassader M, Pagano G (2011) A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med.
21. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, et al. (2011) Acute and Chronic Effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol.
22. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, et al. (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14: 83-90.
23. Mudaliar H, Pegg K, Chadban S, Wu H, Pollock C, et al. (2011) The Role of Toll-Like Receptor Proteins (TLR) 2/4 in Human Proximal Tubular Cells In Vitro- A Potential Mediator of Diabetic Nephropathy? Nephrology 16: 24-43 (Abstract).
24. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, et al. (1997) Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46: 854-859.
25. Ziyadeh FN, Sharma K, Ericksen M, Wolf G, (1994) Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 93: 536-542.
26. Brownlee M, (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
27. Wolf G, Ziyadeh FN, (1997) The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29: 153-163.
28. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, et al. (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91: 9436-9440.
29. Isono M, Cruz MC, Chen S, Hong SW, Ziyadeh FN, (2000) Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 11: 2222-2230.
30. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H, (1995) Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44: 895-899.